TC-D101
/ TCRCure
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 31, 2026
Preliminary Exploratory Clinical Study of TC-D101 in the Treatment of DLL3-Positive Relapsed/Refractory Primary Small-Cell Lung Cancer
(ChiCTR)
- P=N/A | N=8 | Not yet recruiting | Sponsor: Eastern Theater Command General Hospital of the Chinese People's Liberation Army (Jinling Hospital, Affiliated to Nanjing University Medical School);
New trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3 • GRP-10
November 25, 2025
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: TCRCure Biopharma Ltd.
New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1